ClinicalTrials.gg
Active, not recruitingNCT05198284Updated Aug 13, 2026

Prospective Decision Impact Clinical Utility Trial of KidneyIntelX

An observational study in Diabetic Kidney Disease, Chronic Kidney Diseases and Chronic Kidney Disease Stage 1, sponsored by Renalytix AI, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 23 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Renalytix AI, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
23 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.

Planned enrollment
6th of 31
2,000 · median 175
Started
2021
with 12 others
Observational
31 of 153
9 open now
Primary completion
2023-12
later than 0 of 30 live
Registered
122nd of 153
by date
Lead sponsor
4 of 153
Renalytix AI, Inc.

Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 6th largest by planned enrollment of the 31 observational ones that give a count, is one of 13 that started in 2021, is one of 31 observational ones, reaches primary completion later than 0 of the 30 other live ones, and was the 122nd registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 23 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Diabetic Nephropathies with a site in United States, or all of them as a file.
02

Study summary

The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.

03

Conditions studied

  • Diabetic Kidney Disease
  • Chronic Kidney Diseases
  • Chronic Kidney Disease Stage 1
  • Chronic Kidney Disease Stage 2
  • Chronic Kidney Disease Stage 3
04

Who can participate

Ages eligible
23 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Type 2 diabetes and existing chronic kidney disease stages 1-3.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 23 years of age or older.
  • Clinical history of confirmed type 2 diabetes.
  • Evidence of DKD Stages 1-3:
  • Baseline of 30-59 ml/min/1.73m2 (confirmed 3 months apart with at least one value within 1 year prior to enrollment)
  • Individuals with eGFR ≥60 ml/min/1.73m2 and albuminuria (UACR ≥30mg/g)
  • All patients will have a , eGFR, urine albumin and urine creatinine, eGFR, available from within 12 months of enrollment (to be obtained if not clinically available prior).
  • The subject must be able to comprehend and sign an approved form and other applicable study documents.

Exclusion criteria

Exclusion Criteria:

  • Patients with \<30 or ≥ 60 ml/min/1.73m2 without albuminuria.
  • Patients with ESRD or on renal recovery treatments at time of enrollment.
  • Patients who are pregnant at the time of enrollment.
  • Patients who are currently hospitalized.
  • Patients who are currently on Enbrel.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testKidneyIntelX

    KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.

06

What researchers measure

Primary outcomes

  1. Blood pressure

    Proportion (target: 20% increase from prior measurements) of visits in which each participant achieves target blood pressure of \<140/90 mmHg (as per the NKF CKD management guidelines).

    Time frame: 12 Months

  2. HbA1c

    Proportion (target: 20% increase) of patients that achieve individualized target of HbA1c.

    Time frame: 12 Months

  3. ACEi/ARB

    Proportion (target: 20% increase) of patients recently treated with statins and or angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers.

    Time frame: 12 Months

  4. SGLT2/ GLP1

    Proportion (target: 20% increase) of patients recently treated with SGLT2 inhibitors or GLP1 agonists.

    Time frame: 12 Months

  5. Urine albumin to creatinine ratio

    In those with baseline albuminuria, proportion (target: 20%) of patients achieving a 30% decrease in their urine albumin to creatinine ratio from averaged pre-enrollment values to average post-enrollment values through 1 year.

    Time frame: 12 Months

  6. Referrals

    Proportion (target: 20% increase) of patients referred/managed by a dietician, diabetologist, or nephrologist.

    Time frame: 12 Months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Dec 2023, 25 months.

Of 38 observational studies under Diabetic Nephropathies, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 25. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Jan 20, 2022
StartActual
Nov 1, 2021
Primary completionActual
Dec 1, 2023
CompletionEst.
Nov 1, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05198284
Lead sponsor
Renalytix AI, Inc.
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
Nov 1, 2021
Primary completion
Dec 1, 2023
Completion
Nov 1, 2026 (estimated)
Last update
Aug 13, 2026

Study contacts

David W Lam, MD
principal investigator · Mount Sinai Health System

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion